Chloroquine as an anti-autophagy drug in small cell lung cancer (SCLC) patients: A phase I trial to be followed by a phase II trial.
Read time: 1 mins
Last updated:28th Apr 2010
To determine the toxicity of adding chloroquine in escalating doses in SCLC patients: to standard dose cisplatin-etoposide in extensive disease SCLC = STEP 1, and - to standard dose concurrent radiotherapy and cisplatin-etoposide in limited disease SCLC = STEP2
|Study start date||2010-04-28|